Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Nozomi Yamakage"'
Autor:
Hirotaka Matsui, Isao Hirano, Masato Maekawa, Kazunori Ohnishi, Ryuzo Ohno, Kazuyuki Shigeno, Satoki Nakamura, Yoshikazu Sugimoto, Nozomi Yamakage, Tomoki Naoe, Takaaki Ono, Hitoshi Kiyoi, Tadasu Tobita, Akihiro Takeshita, Kaori Shinjo
Publikováno v:
British Journal of Haematology. 146:34-43
Summary The effect of CMC-544, a calicheamicin-conjugated anti-CD22 monoclonal antibody, was analysed in relation to CD22 and P-glycoprotein (P-gp) in B-cell chronic lymphocytic leukaemia (CLL) and non-Hodgkin lymphoma (NHL) in vitro. The cell lines
Autor:
Isao Hirano, Masato Maekawa, Yoshikazu Sugimoto, Nozomi Yamakage, Kaori Shinjo, Akihiro Takeshita, Kazunori Ohnishi, Takaaki Ono, Ryuzo Ohno, Hitoshi Kiyoi, Tomoki Naoe, Satoki Nakamura, Kazuyuki Shigeno, Tadasu Tobita
Publikováno v:
Leukemia. 23:1329-1336
We studied the effect of CMC-544, the calicheamicin-conjugated anti-CD22 monoclonal antibody, used alone and in combination with rituximab, analyzing the quantitative alteration of target molecules, that is, CD20, CD22, CD55 and CD59, in Daudi and Ra
Autor:
Akihiro Takeshita, Yuka Sugimoto, Kazuyuki Shigeno, Nozomi Yamakage, Kazunori Ohnishi, Kaori Shinjo, Takaaki Ono, Isao Hirano, Masato Maekawa, Tadasu Tobita, Tomoki Naoe, Sigeo Nakamura, Hitoshi Kiyoi, Ryuzo Ohno
Publikováno v:
Leukemia. 23:1372-1372
Autor:
Hirotaka Matsui, Nozomi Yamakage, Akihiro Takeshita, Takaaki Ono, Kazuyuki Shigeno, Masato Maekawa, R Ohno, Kazunori Ohnishi, Kaori Shinjo, Satoki Nakamura
Publikováno v:
Web of Science
Rituximab has greatly improved the prognosis of B cell malignancies (BCM). However, several resistance mechanisms have been reported, including the inhibition of apoptosis, complement-dependent cytotoxicity (CDC) and antibody-dependent cellular cytot